Super-Resolution Ultrasound of the Brain in 3D

Last updated: September 3, 2024
Sponsor: Assistance Publique - Hôpitaux de Paris
Overall Status: Active - Recruiting

Phase

N/A

Condition

Stroke

Cerebral Ischemia

Treatment

Transtemporal ultrasound with contrast product (Sonovue)

Clinical Study ID

NCT06133179
APHP230511
  • Ages > 18
  • All Genders

Study Summary

The goal of this proof of concept study is to determine if the visualization of the middle cerebral artery and its perforators, through 3D transtemporal ultrasound imaging, is possible thanks to an off-line analysis by 3D ultrasound localization microscopy. Visualization of these vessels would allow us to conclude on the presence, or absence, of an ischemic stroke in the region of the middle cerebral artery.

To answer the question asked, 20 participants who suffered a stroke will carry out a transtemporal ultrasound examination specifically for research in the 7 days following his stroke. The data obtained will be analyzed by the CNRS medical imaging laboratory, in order to characterize the presence of a stroke and to compare the data obtained with that of standard examinations (CT and MRI).

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • Patient aged 18 and over

  • Hospitalized patient with ischemic stroke in the deep territory of the middlecerebral artery

  • Patient with lesion observable on MRI

  • Patient included between 24 hours and 7 days after the ischemic stroke

  • Patient with a temporal window which allows soundproofing of the polygon of Willisand the middle cerebral artery

  • Patient having signed free, informed and written consent

  • Patient affiliated to a social security system (excluding AME)

Exclusion

Exclusion Criteria:

  • Contralateral middle cerebral artery territory stroke or contralateral middlecerebral artery occlusion

  • Patient with contraindication to Doppler ultrasound with contrast (right-left shunt,severe pulmonary arterial hypertension)

  • Patient with hypersensitivity to the active princip of Sonovue (sulfur hexafluoride)or these excipients

  • Patient with uncontrolled systemic hypertension

  • Patient with respiratory distress syndrome

  • Patient under guardianship or curatorship

  • Pregnant or breastfeeding patient (positive blood pregnancy test duringhospitalization)

  • Patient with damaged skin at the temporal level

  • Patient having presented in the 7 days preceding inclusion an acute coronarysyndrome or suffering from unstable ischemic heart disease

Study Design

Total Participants: 20
Treatment Group(s): 1
Primary Treatment: Transtemporal ultrasound with contrast product (Sonovue)
Phase:
Study Start date:
March 22, 2024
Estimated Completion Date:
February 28, 2025

Connect with a study center

  • Hôpital Bichat

    Paris, Ile de France 75018
    France

    Active - Recruiting

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.